Elucid Raises $27 Million Series B Funding Round To Commercialize A New Paradigm In Heart Disease Diagnosis
Jun 22, 2022•about 3 years ago
Amount Raised
$27 Million
Round Type
series b
Description
Elucid, a company developing a novel, non-invasive medical software to comprehensively characterize cardiovascular disease, announced the closing of a $27 Million Series B financing round. The round was led by an undisclosed strategic investor, with participation from Biovision Ventures, a new Europe-based fund, and existing investors, including MedTex Ventures, IAG Capital, Bold Brain Ventures, and BlueStone Venture Partners.
Funding Insights
Based on industry dataTech investment trends
83% of B2B companies plan digital investments, with 79% prioritizing customer experience tech